Table 3.
General comorbidities according to treatment sequence: reported numbers (%)
| Comorbidities |
Latanoprost/latanoprost–timolol n = 1,592 |
Bimatoprost/bimatoprost–timolol n = 110 |
Travoprost/travoprost–timolol n = 114 |
P-value |
|---|---|---|---|---|
| Blood and lymphatic disorders | 190 (12.2%) | 13 (11.8%) | 15 (13.2%) | 0.94 |
| Cardiac disorders | 810 (51.9%) | 55 (50.0%) | 62 (54.4%) | 0.80 |
| Ear and labyrinth disorders | 807 (51.7%) | 55 (50.0%) | 62 (54.4%) | 0.80 |
| Endocrine disorders | 337 (21.6%) | 22 (20.0%) | 24 (21.1%) | 0.92 |
| Gastrointestinal | 1072 (68.6%) | 70 (63.6%) | 84 (73.7%) | 0.27 |
| Hepatobiliary | 92 (5.9%) | 6 (5.5%) | 5 (4.4%) | 0.79 |
| Musculoskeletal and Connective tissue disorders | 728 (46.6%) | 57 (51.8%) | 59 (51.8%) | 0.35 |
| Nervous system disorders | 656 (42.0%) | 48 (43.6%) | 60 (52.6%) | 0.08 |
| Psychiatric disorders | 129 (8.3%) | 10 (9.1%) | 10 (8.8%) | 0.94 |
| Renal and urinary disorders | 681 (43.6%) | 49 (44.5%) | 47 (41.2%) | 0.86 |
| Respiratory thoracic and Mediastinal disorders | 655 (41.9%) | 47 (42.7%) | 51 (44.7%) | 0.84 |
| Vascular disorders | 905 (57.9%) | 76 (69.1%) | 78 (68.4%) | 0.009 |